Clinical Trial Detail

NCT ID NCT03016871
Title Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors City of Hope Medical Center
Indications

Hodgkin's lymphoma

Therapies

Carboplatin + Etoposide + Ifosfamide + Nivolumab

Age Groups: adult senior child

Additional content available in CKB BOOST